Fut, nem toborozFázis nélkül
Transfemoral Implant of Inovare® Transcatheter Valve
A legfontosabb adatok
- Ki végzi
- Braile Biomedica Ind. Com. e Repr. Ltda.
- Hol
- Brazília4 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 60 fő vett részt
- Kezdés
- 2020. szept. 11.
- Várható befejezés
- 2028. dec. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)
- A regiszteradat frissítve
- 2024. január 11.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 31 feltétel megnézéseKevesebb
Ki vehet részt
- Calcified degenerative aortic stenosis with valve area < 1.0 cm2 (or valve area index < 0.6 cm2/m2) and mean transvalvular gradient > 40 mmHg or aortic jet velocity > 4 m/s by echocardiogram
- Multidisciplinary evaluation by the "Heart Team", composed of a cardiovascular surgeon, clinical cardiologist and hemodynamicist, which concludes that the patient has:; High surgical risk for aortic valve replacement, typically with an STS score of ≥ 8% (or logistic EuroSCORE ≥ 20%) or intermediate risk (STS of ≥ 3% and < 8%); Presence of porcelain aorta or hostile chest, as well as global clinical condition and comorbidities not fully addressed by the score STS; Presence of extreme frailty (5-meter walk test [5MWT], grip strength, activities of daily living (ADL), and albumin laboratory exam); Considerable chance of clinical benefit with the transcatheter procedure
- Heart failure symptoms NYHA functional ≥ II
- Aortic valve annulus with a mean diameter between 17.3 and 28.6 mm, documented by imaging method, suitable for positioning and accommodation of the Inovare® prosthesis, according to the judgment of an experienced hemodynamicist
- Height of coronary ostia > 10 mm or presence of a coronary graft that prevents the occurrence of acute myocardial ischemia due to coronary occlusion after valve release
- Femoral arterial access route considered adequate for the progression of the vascular introducer and prosthesis-balloon system, typically evaluated through multi-imaging methods that include, for example, conventional angiography and computed tomography
- Patient has provided written informed consent to participate in the trial
Ki nem vehet részt
- Hemodynamic instability requiring vasoactive drugs or circulatory support
- Active peptic disease, gastrointestinal bleeding < 3 months, or previously diagnosed bleeding diathesis
- Previous aortic or mitral valve procedure (surgical or by catheter, excluding aortic balloon valvuloplasty)
- Clinical or biological signs of infection with systemic repercussions
- Coronary artery disease requiring elective revascularization during or after the valve procedure
- Evidence of myocardial infarction in an interval of less than one month
- Recent stroke or transient ischemic attack (within the last 6 months)
- Hypersensitivity or contraindication to the administration of heparin, ticlopidine or clopidogrel or to radiopaque contrast
- Life expectancy less than 12 months due to non-cardiac disease or other comorbidities; Anatomical/morphological
- Left ventricular ejection fraction < 30%
- Chronic renal failure on dialysis or with serum creatinine levels > 3.0 mg/dL (265 µmol/L)
- Acute renal failure with serum creatinine that has not yet returned to baseline levels
- Anemia (hemoglobin < 10 g/dl), thrombocytopenia (< 100,000 cells/mm3) or hyperthrombocytosis (> 700,000 cells/mm3)
- Clinic
- Valve procedure with clinical need to be performed in a time of urgency or emergency (non-elective)
- Endocarditis < 12 months
- Need for chronic anticoagulation for other causes
- Valve ring diameter less than or equal to 17.2 mm or greater than or equal to 28.7 mm
- Iliofemoral access route, with extreme tortuosity or calcification or reduced luminal diameter (typically < 7 mm), which prevents safe progression of the arterial introducer and delivery system with the prosthesis, according to the judgment of the responsible physician
- Presence of sessile and unstable atheromas in the ascending aorta and/or aortic arch detected by imaging methods
- Obstructive hypertrophic cardiomyopathy or severe left ventricular outflow tract obstruction, with no possibility of balloon dilation
- Moderate or severe aortic, mitral or tricuspid regurgitation
- Non-calcified native valve
- Evidence of an intracardiac mass (tumor, thrombus, or vegetation)
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Clinical trial to evaluate the early safety and efficacy of the transfemoral implant of Inovare® Transcatheter Valve for the treatment of patients with severe degenerative aortic stenosis and high surgical risk.
A vizsgálat csoportja
- TAVI TRANSFEMORALA vizsgált kezelés
Kezelés: INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Transfemoral Implant of Inovare® Transcatheter Valve - Clinical Trial of Feasibility and Safety and Efficacy Verification
- A regiszteradat frissítve
- 2024. január 11.